BDLSF (Inoviq) 3-Month Share Buyback Ratio: 0.00% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BDLSF Inoviq Ltd BDLSF
27 GF Score
Price $0.12
GF Value $0.29
! 2 Warning Signs
View Full Analysis

What is Inoviq 3-Month Share Buyback Ratio?

Inoviq BDLSF 27 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus rates BDLSF with a GF Score™ of 27/100 and a GF Value™ of $0.29. The stock has 2 warning signs investors should review.

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.

BDLSF
27GF Score
Inoviq Ltd BDLSF
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 3-Month Share Buyback Ratio of 0.00 mean?
Inoviq (BDLSF) has a 3-Month Share Buyback Ratio of 0.00 as of Dec. 2025. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Inoviq and its competitors.
Is Inoviq's 3-Month Share Buyback Ratio too high?
Inoviq's current 3-Month Share Buyback Ratio is 0.00. Overall, Inoviq has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Inoviq's 3-Month Share Buyback Ratio compare to TMO and DHR?
Inoviq's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Medical Diagnostics & Research company?
A good 3-Month Share Buyback Ratio depends on the Medical Diagnostics & Research industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Inoviq and its competitors. Inoviq's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inoviq stock overvalued right now?
Inoviq (BDLSF) has a current 3-Month Share Buyback Ratio of 0.00. The stock's GF Value™ is $0.29, compared to a current price of $0.12 — trading 58.6% below its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Inoviq's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Inoviq (BDLSF), the current 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inoviq (BDLSF) Overvalued in 2026?

Based on GuruFocus' analysis, Inoviq stock appears to be undervalued. The current stock price of $0.12 is trading 58.6% below its estimated GF Value™ of $0.29.

Key valuation signals for BDLSF:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: $0.29 vs. price of $0.12 (58.6% below fair value)
  • GF Score™: 27/100 with 2 warning signs

No single metric tells the full story. See the BDLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inoviq Business Description

Other Exchanges IIQ:Australia
Address 23 Normanby Road, Notting Hill, Melbourne, VIC, AUS, 3168
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.
27GF Score

Get the complete analysis for BDLSF

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.12
Price
$0.29
GF Value